ArticleBlood cancer journal2023

A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis.

Jayastu Senapati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.